J.P. Morgan

Analysts Review Gilead Sciences, Inc. Earnings (GILD)

Analysts are weighing in this afternoon on Gilead Sciences, Inc. (NASDAQ:GILD), after the U.

Stuart Colby Editor — July 28, 2015, 5:34 PM EDT

J.P. Morgan Maintains Overweight on Novavax, Inc. (NVAX) Following Positive Results in Phase 1 Ebola Vaccine Trial

J.P.

Jason Cohen Jason Cohen — July 21, 2015, 1:20 PM EDT

J.P. Morgan Provides Takeaways on Juno Therapeutics Inc (JUNO) Following Meeting with Management

Shares of Juno Therapeutics Inc (NASDAQ:JUNO) closed yesterday up 15% following the announcement of the company’s collaboration with Celgene Corporation. In response, J.

Jason Cohen Jason Cohen — July 1, 2015, 10:14 AM EDT

J.P. Morgan Positive on Alibaba Group Holding Ltd (BABA)’s Long Term Outlook

J.P.

Scott Fields Scott Fields — June 16, 2015, 12:44 PM EDT

J.P. Morgan Initiates Coverage on Idera Pharmaceuticals Inc; Sees 60% Upside For The Stock

J.P.

Kate George, Editor — June 15, 2015, 10:00 AM EDT

J.P. Morgan Offers Insight Into bluebird bio Inc (BLUE) Collaboration With Celgene Corporation (CELG)

In research report issued today, J.P.

Jason Cohen Jason Cohen — June 4, 2015, 11:55 AM EDT

Juno Therapeutics Inc (JUNO)’s Multiple Sources of Technology May Prove To Be A Competitive Advantage Over Time: J.P. Morgan

Juno Therapeutics Inc (NASDAQ:JUNO) shares have taken off, adding 13.72% to trade at $60.

Jason Cohen Jason Cohen — June 2, 2015, 10:53 AM EDT

J.P. Morgan Provides Key Takeaways From Juno Therapeutics Inc ASCO Presentations

J.P.

Jason Cohen Jason Cohen — June 1, 2015, 8:29 PM EDT

J.P. Morgan Offers Commentary on Celgene Corporation Following Positive Data For Revlimid

J.P.

Jason Cohen Jason Cohen — June 1, 2015, 4:25 PM EDT

J.P. Morgan Shines Light on Juno Therapeutics Inc (JUNO) Deal With Editas Medicine

J.P.

Jason Cohen Jason Cohen — May 27, 2015, 5:49 PM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts